(19)
(11) EP 1 060 194 A1

(12)

(43) Date of publication:
20.12.2000 Bulletin 2000/51

(21) Application number: 99908399.1

(22) Date of filing: 24.02.1999
(51) International Patent Classification (IPC)7C07K 19/00
// (C07K14/52, 14:55, 14:705, 14:73)
(86) International application number:
PCT/US9903/966
(87) International publication number:
WO 9943/713 (02.09.1999 Gazette 1999/35)
(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE
Designated Extension States:
LT LV RO SI

(30) Priority: 25.02.1998 US 75887 P

(71) Applicant: Lexigen Pharmaceuticals Corp.
Lexington, MA 02421 (US)

(72) Inventors:
  • GILLIES, Stephen, D.
    Carlisle, MA 01741 (US)
  • LO, Kin-Ming
    Lexington, MA 02173 (US)
  • LAN, Yan
    Belmont, MA 02178 (US)
  • WESOLOWSKI, John
    Weymouth, MA 02189 (US)

(74) Representative: Benz, Jürgen, Dr. 
c/o Merck Patent GmbH,Postfach
64271 Darmstadt
64271 Darmstadt (DE)

   


(54) ENHANCING THE CIRCULATING HALF-LIFE OF ANTIBODY-BASED FUSION PROTEINS